

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1246)

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Director(s)**”) of Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces (i) the resignation of Mr. Chan Chi Keung, Billy (“**Mr. Chan**”) as an independent non-executive Director; and (ii) the appointment of Ms. Tang Man Yi (“**Ms. Tang**”) as an independent non-executive Director, both with effect from 27 January 2024.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that, Mr. Chan has tendered his resignation as an independent non-executive Director with effect from 27 January 2024.

Mr. Chan has confirmed to the Company that his resignation was due to his intention to focus on his other business pursuits and commitments. Mr. Chan has confirmed to the Company that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Chan for his valuable contribution to the Company during his tenure of service.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Ms. Tang Man Yi (“**Ms. Tang**”) has been appointed as an independent non-executive Director with effect from 27 January 2024.

Ms. Tang, aged 57, obtained a bachelor degree in Social Science from the University of Hong Kong in 1989 and a master degree in Corporate Finance from the Hong Kong Polytechnic University in 2011. She has over 30 years of professional experience in the audit, finance and accounting fields, including over 10 years of audit working experience in both Hong Kong and Shenzhen offices of a big four international audit firm. Ms. Tang has been qualified as a member of Hong Kong Institute of Certified Public Accountants. Ms. Tang has held the present position of director at CNG Partners CPA Limited since 2015.

The Company will enter into an appointment letter with Ms. Tang for a term of three years commencing from 27 January 2024, which will be automatically renewed for successive one-year periods, subject to termination by either party giving at least one month’s written notice. Ms. Tang is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Ms. Tang is entitled to receive an annual emolument of HK\$120,000, which was determined by the Board upon the recommendation of the remuneration committee of the Company (the “**Remuneration Committee**”) with reference to her duties and responsibilities and the prevailing market conditions. Ms. Tang’s remuneration is subject to review by the Remuneration Committee and the Board from time to time.

Save as disclosed above, as at the date of this announcement, Ms. Tang (i) does not hold any positions with any members of the Group; (ii) does not hold any directorships in any other public companies listed in Hong Kong or overseas in the last three years or other major appointments or professional qualifications; (iii) does not have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Ms. Tang has confirmed (i) her independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); (ii) that she has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, and there is no other matter in relation to the appointment of Ms. Tang that needs to be brought to the attention of the Shareholders.

The Board would like to express its warm welcome to Ms. Tang in joining the Board.

CHANGES IN COMPOSITION OF BOARD COMMITTEES

The Board further announces that, with effect from 27 January 2024:

- (1) Upon Mr. Chan's resignation as independent non-executive Director, Mr. Chan will cease to be the chairman of the audit committee of the Company (the "**Audit Committee**") and a member of the Remuneration Committee; and
- (2) Ms. Tang has been appointed as the chairlady of the Audit Committee and a member of the Remuneration Committee.

By order of the Board
Boill Healthcare Holdings Limited
Qiu Dongfang
Executive Director and Chairman

Hong Kong, 26 January 2024

As at the date of this announcement, the Company has (i) three executive Directors, namely Mr. Qiu Dongfang, Mr. Qiu Bin and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung, Billy, Mr. Yi Baxian, and Mr. Wang Zhe.